Innovation Bio Signs Next-Generation Antibody CDMO Agreement with JinScript ProBio

"IBA-101, Next-Generation CD47 Neutralizing Antibody Addressing Anemia Caused by Red Blood Cell Destruction"

Brian Min, CEO of Jin Script Pro Bio (left), and Seunggu Kim, CEO of Innovation Bio, are posing for a commemorative photo.
[Photo by Innovation Bio]

[Asia Economy Reporter Lee Gwan-joo] Innovation Bio, an investment company of Ewonn Compotech, announced on the 26th that it has signed a contract with global bio contract development and manufacturing organization (CDMO) JinScript ProBio for the contract development and manufacturing of clinical sample materials of the immune-oncology CD47 neutralizing antibody.

Innovation Bio is a bio company developing biomarkers, CAR-T cell therapies, and antibody therapeutics. Through this contract, it plans to produce cell lines for the next-generation immune checkpoint inhibitor CD47 neutralizing antibody, which has recently attracted attention, as well as non-clinical and clinical trial samples.

CD47 is an important protein that prevents normal cells in our body from being attacked by immune cells. However, cancer cells also use this protein to defend against attacks from immune cells. CD47 neutralizing antibodies inhibit the cancer cells’ immune evasion mechanism, promoting phagocytosis of cancer cells by macrophages and enhancing anti-cancer immune responses.

CD47 neutralizing antibodies are the next-generation immune checkpoint inhibitors receiving the most attention after PD-1/PD-L1 inhibitors. Just as existing PD-1/PD-L1 inhibitors are administered in combination with other anticancer drugs, CD47 neutralizing antibodies can also be combined with various anticancer agents, making their value very high. Recently, global pharmaceutical companies such as Gilead and Pfizer have shown high expectations by making aggressive investments in CD47 neutralizing antibodies.

'IBA-101,' developed by Innovation Bio, is a next-generation CD47 neutralizing antibody that solves problems such as anemia caused by red blood cell destruction observed in clinical trials of existing CD47 neutralizing antibodies. The company explained that it secured excellent results in in vitro and in vivo efficacy and toxicity tests using humanized mice.

Brian Min, CEO of JinScript ProBio, said, "Our rich CMC and GMP manufacturing experience, recognized by global big pharma, will greatly contribute to accelerating the antibody drug development of the innovative biopharmaceutical company Innovation Bio." He added, "We expect that more patients will benefit from this."

Kim Seung-gu, CEO of Innovation Bio, said, "Through this contract, IBA-101 will enter domestic clinical trials in a short period." He added, "Together with Ewonn Compotech and the research and development team of Professor Scott A. Worldman at Thomas Jefferson University Hospital in the U.S., we expect to swiftly proceed to U.S. FDA clinical trials."

This content was produced with the assistance of AI translation services.